J&J's Actelion Deal Just One More Reason to Buy Shares

As consumers across the U.S. eye deals on Black Friday, one of America's largest health care product makers is seeking a special purchase of its own.

Following speculation, Switzerland-based biotech Actelion (ALIOF) confirmed that it is currently a takeover target for Johnson & Johnson (JNJ) . And if the acquisition succeeds, it could be worth nearly $20 billion.

Investors on both sides of the deal were pleased. In Friday trading, they sent Johnson & Johnson's stock up over 1% and Actelion shares up by nearly 20%.

Actelion's drug portfolio includes popular treatments for pulmonary arterial hypertension (PAH), which can lead to heart failure if left untreated. Its drug Tracleer was for years the American cardiologist's go-to drug for PAH, but it lost its patent protection in November 2015.

However, this year, Actelion's newer PAH therapies, Opsumit and Uptravi, saw sales that blew past those of Tracleer for the first time. That recently led the company to up its earnings guidance for the third time in 2016.

Prior to news of an offer on Thursday, Actelion shares had seen a year-to-date boost of about 13%, giving it a market value around $17 billion.

If you liked this article you might like

Johnson & Johnson Moves Forward with Actelion Purchase After EU Approval

News Out of Europe: Johnson & Johnson Buys Actelion

Johnson & Johnson Buys Actelion for $30 Billion

Global Stocks Are Following Wall Street Higher as Dow Hits 20,000

Johnson & Johnson CEO Talks Trump, Taxes and M&A After Mixed Earnings